MRSN Research and Charts

MRSN - Mersana Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-12 (Delayed quote data 2025-06-30)

Last 0.30	Change ⇑ +0.01 (+0.00%)	Volume 3,571,261
	Open 0.32	High 0.32	Low 0.28

8EMA (Daily) 0.33	40EMA (Daily) 0.36	50EMA (Daily) 0.38	STO (Daily) 8.266	MACD Hist (Daily) -0.014
8EMA (Weekly) 0.341	40EMA (Weekly) 0.90	50EMA (Weekly) 1.10	STO (Weekly) 33.117	MACD Hist (Weekly) 0.095


Company Profile
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.